| Home | Log In | Register | Our Services | My Account | Contact | Help |
You are NOT currently logged in
OXFORD PHARMASCIENCE GROUP (OXP)
dreamcatcher
- 13 Sep 2012 19:53
http://oxfordpharmascience.com/Oxford Pharmascience is a drug development company that re-develops approved drugs to make them better, safer and easier to take.
Oxford Pharmascience is using its proprietary oral drug delivery technologies to develop improved formulations of non-steroidal anti-inflammatory drugs (NSAIDs) and statins for global markets.
The Company's risk-diversified pipeline of prescription and OTC medicines is focused on cardiovascular disease and pain relief indications. Since the products incorporate previously approved drugs, this reduces risk and results in a simplified drug development regulatory pathway allowing less expensive development programs and faster access to market.
The Company has also commercialized calcium/vitamin D chews that taste better and dissolve faster than currently available regular formats. These products are now marketed in the UK, Middle East and Brazil.
Oxford Pharmascience is located in the UK and is led by a highly experienced management team that directs and manages the outsourcing of its development; pre-clinical and clinical programs; and manufacturing to a trusted network of partners and suppliers.
The Company commercializes its portfolio of product opportunities through out-licensing to leading pharmaceutical companies worldwide. Currently the Company has partnerships with Aché Laboratories and Bayer.
Oxford Pharmascience (LON:OXP) was established by a team of entrepreneurs in 2008 and is a publicly listed company on London's Alternative Investment Market (AIM), with a strong blue chip investor base.
robertalexander
- 25 Jul 2013 16:17
- 72 of 182
when can AIM shares be added to ISAs [i know its Autumn but not sure when datewise] and will it be all AIM shares or just certain ones[ie the larger companies] as i would like to add these and SAR to my ISA.
Alex
Alex
dreamcatcher
- 25 Jul 2013 16:27
- 73 of 182
dreamcatcher
- 25 Jul 2013 16:38
- 74 of 182
Oxford Pharmascience's new UCL deal is a "win-win"
By John Harrington July 25 2013, 12:44pm The compounds being looked at are already on the market, which means the route to market for new variations should be relatively swift.The compounds being looked at are already on the market, which means the route to market for new variations should be relatively swift.
Drug delivery specialist Oxford Pharmascience (LON:OXP) has extended and deepened its collaboration with the University College London (UCL) and the university's well-regarded Phloral technology.
The new agreement gives Oxford Pharma an option over a further 53 compounds that it could commercialise using the university’s know-how.
The company is already working with UCL on re-formulations of generic statins Atorvastatin and Simvastatin to reduce their side effects, and the new deal will see Oxford Pharma get first pick of a different batch of compounds.
“It’s the same technology that we’re licensing,” Nigel Theobald, Oxford Pharma’s chief executive, explained to Proactive Investors. That technology is a more effective drug delivery system that, in essence, achieves the same effect as regular drugs but with smaller dosages.
“There are lots of other drugs out there where there are side-effects caused from metabolism in the Cy [Cytochrome] P450 system,” he added. Cy-P450 enzymes are essential for the metabolism of many medications.
The new deal gives Oxford Pharma until March next year to investigate the potential for the 53 compounds with an option to work for another year on those that have the best commercial and clinical potential.
In fact, the company has already been doing some preliminary work on the testing, indicating that the relationship between UCL and Oxford Pharma is a healthy and potentially productive one.
Speaking about the compounds, Theobald said: “Some of them could have a very strong commercial need, and a very strong clinical need, and could work very well with our technology. All three of those things we are investigating.”
Theobald said that Oxford Pharma and UCL have yet to agree on the terms of any licensing arrangement that arises from the new deal have, but they are likely to be similar to the terms already agreed for statins.
“We’re just pushing on and trying to get the greatest commercial opportunities out of it [the relationship]. They’re delighted, and we’re delighted. It’s a good win-win,” Theobald said.
Just as importantly, the deal closes the door to any competitor that might have been interested in getting a look at these compounds.
“Having already told the world how to do it, we want to make sure that people don’t try to get in ahead of us,” the Oxford Pharma chief executive said.
It is classic Oxford Pharmascience procedure, exploring and developing better options of existing drugs.
“All of the compounds are on the market. A good chunk of them are already generic, and some are coming off-patent very soon,” Theobald revealed.
"Our focus on reformulating existing medicines to make them safer and easier to take is now gathering strong momentum with our programmes for NSAIDs (non-steroidal anti-inflammatory drugs) and statins.
“There are many other drugs widely used where side effects reduce the tolerance or compliance in patients.
“This option allows us to explore a range of potential drug candidates which fit with this strategy without taking our eyes off the existing programmes.”
Theobald was keen to emphasise that last point about the new deal not being a distraction to the company’s existing work programmes.
“The redevelopment work that we do will be quick and it will be relatively cheap,” Theobald said.
Shares in Oxford Pharmascience were up 1.8% at 3.74p in lunch-time trading.
By John Harrington July 25 2013, 12:44pm The compounds being looked at are already on the market, which means the route to market for new variations should be relatively swift.The compounds being looked at are already on the market, which means the route to market for new variations should be relatively swift.
Drug delivery specialist Oxford Pharmascience (LON:OXP) has extended and deepened its collaboration with the University College London (UCL) and the university's well-regarded Phloral technology.
The new agreement gives Oxford Pharma an option over a further 53 compounds that it could commercialise using the university’s know-how.
The company is already working with UCL on re-formulations of generic statins Atorvastatin and Simvastatin to reduce their side effects, and the new deal will see Oxford Pharma get first pick of a different batch of compounds.
“It’s the same technology that we’re licensing,” Nigel Theobald, Oxford Pharma’s chief executive, explained to Proactive Investors. That technology is a more effective drug delivery system that, in essence, achieves the same effect as regular drugs but with smaller dosages.
“There are lots of other drugs out there where there are side-effects caused from metabolism in the Cy [Cytochrome] P450 system,” he added. Cy-P450 enzymes are essential for the metabolism of many medications.
The new deal gives Oxford Pharma until March next year to investigate the potential for the 53 compounds with an option to work for another year on those that have the best commercial and clinical potential.
In fact, the company has already been doing some preliminary work on the testing, indicating that the relationship between UCL and Oxford Pharma is a healthy and potentially productive one.
Speaking about the compounds, Theobald said: “Some of them could have a very strong commercial need, and a very strong clinical need, and could work very well with our technology. All three of those things we are investigating.”
Theobald said that Oxford Pharma and UCL have yet to agree on the terms of any licensing arrangement that arises from the new deal have, but they are likely to be similar to the terms already agreed for statins.
“We’re just pushing on and trying to get the greatest commercial opportunities out of it [the relationship]. They’re delighted, and we’re delighted. It’s a good win-win,” Theobald said.
Just as importantly, the deal closes the door to any competitor that might have been interested in getting a look at these compounds.
“Having already told the world how to do it, we want to make sure that people don’t try to get in ahead of us,” the Oxford Pharma chief executive said.
It is classic Oxford Pharmascience procedure, exploring and developing better options of existing drugs.
“All of the compounds are on the market. A good chunk of them are already generic, and some are coming off-patent very soon,” Theobald revealed.
"Our focus on reformulating existing medicines to make them safer and easier to take is now gathering strong momentum with our programmes for NSAIDs (non-steroidal anti-inflammatory drugs) and statins.
“There are many other drugs widely used where side effects reduce the tolerance or compliance in patients.
“This option allows us to explore a range of potential drug candidates which fit with this strategy without taking our eyes off the existing programmes.”
Theobald was keen to emphasise that last point about the new deal not being a distraction to the company’s existing work programmes.
“The redevelopment work that we do will be quick and it will be relatively cheap,” Theobald said.
Shares in Oxford Pharmascience were up 1.8% at 3.74p in lunch-time trading.
dreamcatcher
- 29 Jul 2013 21:48
- 75 of 182
SMALL CAPS SHARE TIPS: Uni tie-up and statins breakthrough gives Oxford Pharmascience a shot in the arm
By John Harrington, Proactive Investors
PUBLISHED: 17:43, 29 July 2013 | UPDATED: 18:10, 29 July 2013
Shares in Oxford Pharmascience continue to perform well as investors sharpen their focus on its innovative work with University College London.
Investors appear keen to back the company which has just inked a new deal to extend and deepen its collaboration with UCL and the university's well-regarded Phloral technology.
The idea is that together they will apply innovative drug delivery technology, which will allow more effective dosing, and hopefully reduce side-effects as a result. The partners have already had success with this kind of work on statins, a cholesterol busting drug.
Under the microscope: Oxford Pharmascience has deals in place to commercialise further UCL scientific breakthroughs.
One of the major problems with statins is that many users suffer unpleasant side effects such as inflammation and muscle damage.
A lower dosage would result in fewer side effects, but also, under normal circumstances, be less effective in lowering the patient’s cholesterol level.
However, Oxford Pharma has reformulated two of the most widely used generic statins, Atorvastatin and Simvastatin, which will allow them to be delivered to the colon where they are more effectively absorbed into the liver.
The new agreement, signed last week, gives Oxford Pharma an option over a further 53 compounds that it could commercialise using the UCL’s know-how.
The new deal will see Oxford Pharma get first pick of a different batch of compounds.
.
'It’s the same technology that we’re licensing,' Nigel Theobald, Oxford Pharma’s chief executive, explained to Proactive Investors.
Oxford Pharma has until March next year to investigate the potential for the 53 compounds and it can then spend another year assessing those with the best commercial and clinical potential.
Speaking about the compounds, Theobald said: 'Some of them could have a very strong commercial need, and a very strong clinical need, and could work very well with our technology. All three of those things we are investigating.'
Oxford Pharma and UCL have yet to agree on the terms of any licensing arrangements should these programmes lead to commercial products, but it is likely that any deal would be similar to the terms to other existing terms for statins.
Hargreaves Isa Guide 2
'We’re just pushing on and trying to get the greatest commercial opportunities out of it [the relationship]. They’re delighted, and we’re delighted. It’s a good win-win,' Theobald said.
Just as importantly, the deal closes the door to any competitor that might have been interested in getting a look at these compounds.
'Having already told the world how to do it, we want to make sure that people don’t try to get in ahead of us.'
It is classic Oxford Pharmascience procedure, exploring and developing better options of existing drugs.
'All of the compounds are on the market. A good chunk of them are already generic, and some are coming off-patent very soon,' Theobald revealed.
'Our focus on reformulating existing medicines to make them safer and easier to take is now gathering strong momentum with our programmes for NSAIDs (non-steroidal anti-inflammatory drugs) and statins.
'There are many other drugs widely used where side effects reduce the tolerance or compliance in patients. This option allows us to explore a range of potential drug candidates which fit with this strategy without taking our eyes off the existing programmes.'
Theobald was keen to emphasise that last point about the new deal not being a distraction to the company’s existing work programmes.
'The redevelopment work that we do will be quick and it will be relatively cheap,' Theobald said.
By John Harrington, Proactive Investors
PUBLISHED: 17:43, 29 July 2013 | UPDATED: 18:10, 29 July 2013
Shares in Oxford Pharmascience continue to perform well as investors sharpen their focus on its innovative work with University College London.
Investors appear keen to back the company which has just inked a new deal to extend and deepen its collaboration with UCL and the university's well-regarded Phloral technology.
The idea is that together they will apply innovative drug delivery technology, which will allow more effective dosing, and hopefully reduce side-effects as a result. The partners have already had success with this kind of work on statins, a cholesterol busting drug.
Under the microscope: Oxford Pharmascience has deals in place to commercialise further UCL scientific breakthroughs.
One of the major problems with statins is that many users suffer unpleasant side effects such as inflammation and muscle damage.
A lower dosage would result in fewer side effects, but also, under normal circumstances, be less effective in lowering the patient’s cholesterol level.
However, Oxford Pharma has reformulated two of the most widely used generic statins, Atorvastatin and Simvastatin, which will allow them to be delivered to the colon where they are more effectively absorbed into the liver.
The new agreement, signed last week, gives Oxford Pharma an option over a further 53 compounds that it could commercialise using the UCL’s know-how.
The new deal will see Oxford Pharma get first pick of a different batch of compounds.
.
'It’s the same technology that we’re licensing,' Nigel Theobald, Oxford Pharma’s chief executive, explained to Proactive Investors.
Oxford Pharma has until March next year to investigate the potential for the 53 compounds and it can then spend another year assessing those with the best commercial and clinical potential.
Speaking about the compounds, Theobald said: 'Some of them could have a very strong commercial need, and a very strong clinical need, and could work very well with our technology. All three of those things we are investigating.'
Oxford Pharma and UCL have yet to agree on the terms of any licensing arrangements should these programmes lead to commercial products, but it is likely that any deal would be similar to the terms to other existing terms for statins.
Hargreaves Isa Guide 2
'We’re just pushing on and trying to get the greatest commercial opportunities out of it [the relationship]. They’re delighted, and we’re delighted. It’s a good win-win,' Theobald said.
Just as importantly, the deal closes the door to any competitor that might have been interested in getting a look at these compounds.
'Having already told the world how to do it, we want to make sure that people don’t try to get in ahead of us.'
It is classic Oxford Pharmascience procedure, exploring and developing better options of existing drugs.
'All of the compounds are on the market. A good chunk of them are already generic, and some are coming off-patent very soon,' Theobald revealed.
'Our focus on reformulating existing medicines to make them safer and easier to take is now gathering strong momentum with our programmes for NSAIDs (non-steroidal anti-inflammatory drugs) and statins.
'There are many other drugs widely used where side effects reduce the tolerance or compliance in patients. This option allows us to explore a range of potential drug candidates which fit with this strategy without taking our eyes off the existing programmes.'
Theobald was keen to emphasise that last point about the new deal not being a distraction to the company’s existing work programmes.
'The redevelopment work that we do will be quick and it will be relatively cheap,' Theobald said.
doodlebug4 - 02 Aug 2013 12:15 - 76 of 182
RNS
RNS Number : 8525K
Oxford Pharmascience Group PLC
02 August 2013
Oxford Pharmascience Group plc
("Oxford Pharmascience" or "the Company")
Oxford Pharmascience establishes Scientific Advisory Board
Oxford Pharmascience, the specialty pharmaceutical company that redevelops medicines to make them better, safer and easier to take, today announces establishment of a scientific advisory board to support its medicines reformulation programme.
The Scientific Advisory Board shall consist of the Chief Technology Officer and independent world class experts, providing a broad range of expertise in both basic and clinical sciences, as well as technologies. The Scientific Advisory Board will function as a broadly knowledgeable and objective group of scientists and non-scientists to consider and report periodically to the Board on matters relating to the investment in the Company's research and development and technology initiatives. The Scientific Advisory Board may also suggest specialist advisers and work closely with them to help progress elements of the Company's business.
As a first step, the company is appointing Professor Bill Dawson to serve on the scientific advisory board. Bill Dawson retired from Eli Lilly and Co in 1996 after 27 years where he was Research Director for 14 years and took 15 compounds into development, two of which reached the market. Bill is currently a non-executive director of Proteome Sciences Plc, and Antitope Ltd as well as a member of a number of corporate Scientific Advisory Boards. He is Chairman of the Academy of Pharmaceutical Sciences and a Visiting Professor at the UCL School of Pharmacy. He is a member of the Expert Panel advising the Stevenage Bioscience Catalyst.
Marcelo Bravo, Chief Technology Officer of Oxford Pharmascience commented, "The establishment of a world class Scientific Advisory Board to guide the company's development programme will help us accelerate progress into specific medicine development programmes. Professor Dawson's experience in the design, selection and progression of new medicines through optimal R&D programmes is invaluable as we enter a new stage as a company. We plan to continue building the Scientific Advisory Board with further appointments in the coming months."
RNS Number : 8525K
Oxford Pharmascience Group PLC
02 August 2013
Oxford Pharmascience Group plc
("Oxford Pharmascience" or "the Company")
Oxford Pharmascience establishes Scientific Advisory Board
Oxford Pharmascience, the specialty pharmaceutical company that redevelops medicines to make them better, safer and easier to take, today announces establishment of a scientific advisory board to support its medicines reformulation programme.
The Scientific Advisory Board shall consist of the Chief Technology Officer and independent world class experts, providing a broad range of expertise in both basic and clinical sciences, as well as technologies. The Scientific Advisory Board will function as a broadly knowledgeable and objective group of scientists and non-scientists to consider and report periodically to the Board on matters relating to the investment in the Company's research and development and technology initiatives. The Scientific Advisory Board may also suggest specialist advisers and work closely with them to help progress elements of the Company's business.
As a first step, the company is appointing Professor Bill Dawson to serve on the scientific advisory board. Bill Dawson retired from Eli Lilly and Co in 1996 after 27 years where he was Research Director for 14 years and took 15 compounds into development, two of which reached the market. Bill is currently a non-executive director of Proteome Sciences Plc, and Antitope Ltd as well as a member of a number of corporate Scientific Advisory Boards. He is Chairman of the Academy of Pharmaceutical Sciences and a Visiting Professor at the UCL School of Pharmacy. He is a member of the Expert Panel advising the Stevenage Bioscience Catalyst.
Marcelo Bravo, Chief Technology Officer of Oxford Pharmascience commented, "The establishment of a world class Scientific Advisory Board to guide the company's development programme will help us accelerate progress into specific medicine development programmes. Professor Dawson's experience in the design, selection and progression of new medicines through optimal R&D programmes is invaluable as we enter a new stage as a company. We plan to continue building the Scientific Advisory Board with further appointments in the coming months."
dreamcatcher
- 02 Aug 2013 13:59
- 77 of 182
Oxford Pharmascience sets up Scientific Advisory Board
By John Harrington
August 02 2013, 1:18pm Professor Dawson is chairman of the Academy of Pharmaceutical Sciences and a visiting professor at the UCL School of Pharmacy. He is also a member of the Expert Panel advising the Stevenage Bioscience Catalyst.Professor Dawson is chairman of the Academy of Pharmaceutical Sciences and a visiting professor at the UCL School of Pharmacy. He is also a member of the Expert Panel advising the Stevenage Bioscience Catalyst.
Medicines reformulation specialist Oxford Pharmascience (LON:OXP) is setting up what it describes as a “world class” Scientific Advisory Board to support its development programme.
Marcelo Bravo, chief technology officer of Oxford Pharmascience, will be on the Scientific Advisory Board, as will a number of independent experts, starting with Professor Bill Dawson, a former leading light at US pharmaceuticals giant Eli Lilly.
Professor Dawson retired from Eli Lilly in 1996 after 27 years where he was director of Research for 14 years. During his time at the US pharmaceuticals company he took 15 compounds into development, two of which reached the market.
He is currently a non-executive director of Proteome Sciences plc, and Antitope Ltd as well as a member of a number of corporate Scientific Advisory Boards.
Further appointments to this team of experts will be made in the coming months. The idea is for the board to have a broad range of skills, experiences and fields of expertise, extending beyond the world of science into areas such as technology.
Oxford Pharmascience said the Scientific Advisory Board will report periodically to the Oxford Pharma board on matters relating to the investment in the company's research and development and technology initiatives. The Scientific Advisory Board may also suggest specialist advisers and work closely with them to help progress elements of the company's business.
"The establishment of a world class Scientific Advisory Board to guide the company's development programme will help us accelerate progress into specific medicine development programmes,” Bravo explained.
“Professor Dawson's experience in the design, selection and progression of new medicines through optimal R&D [research & development] programmes is invaluable as we enter a new stage as a company,” he added.
The creation of this brains trust follows a week after the drug delivery specialist extended and deepened its collaboration with the University College London (UCL) and the university's well-regarded Phloral technology.
The deal gave Oxford Pharma first dibs on 53 compounds that it could commercialise using the university’s know-how.
“All of the compounds are on the market. A good chunk of them are already generic, and some are coming off-patent very soon,” Oxford Pharmascience chief executive Nigel Theobald revealed to Proactive Investors last week.
In keeping with Oxford Pharmascience's normal strategy, the company will be looking to see if it can reformulate the compounds, making them more effective and therefore suitable for commercial release.
By John Harrington
August 02 2013, 1:18pm Professor Dawson is chairman of the Academy of Pharmaceutical Sciences and a visiting professor at the UCL School of Pharmacy. He is also a member of the Expert Panel advising the Stevenage Bioscience Catalyst.Professor Dawson is chairman of the Academy of Pharmaceutical Sciences and a visiting professor at the UCL School of Pharmacy. He is also a member of the Expert Panel advising the Stevenage Bioscience Catalyst.
Medicines reformulation specialist Oxford Pharmascience (LON:OXP) is setting up what it describes as a “world class” Scientific Advisory Board to support its development programme.
Marcelo Bravo, chief technology officer of Oxford Pharmascience, will be on the Scientific Advisory Board, as will a number of independent experts, starting with Professor Bill Dawson, a former leading light at US pharmaceuticals giant Eli Lilly.
Professor Dawson retired from Eli Lilly in 1996 after 27 years where he was director of Research for 14 years. During his time at the US pharmaceuticals company he took 15 compounds into development, two of which reached the market.
He is currently a non-executive director of Proteome Sciences plc, and Antitope Ltd as well as a member of a number of corporate Scientific Advisory Boards.
Further appointments to this team of experts will be made in the coming months. The idea is for the board to have a broad range of skills, experiences and fields of expertise, extending beyond the world of science into areas such as technology.
Oxford Pharmascience said the Scientific Advisory Board will report periodically to the Oxford Pharma board on matters relating to the investment in the company's research and development and technology initiatives. The Scientific Advisory Board may also suggest specialist advisers and work closely with them to help progress elements of the company's business.
"The establishment of a world class Scientific Advisory Board to guide the company's development programme will help us accelerate progress into specific medicine development programmes,” Bravo explained.
“Professor Dawson's experience in the design, selection and progression of new medicines through optimal R&D [research & development] programmes is invaluable as we enter a new stage as a company,” he added.
The creation of this brains trust follows a week after the drug delivery specialist extended and deepened its collaboration with the University College London (UCL) and the university's well-regarded Phloral technology.
The deal gave Oxford Pharma first dibs on 53 compounds that it could commercialise using the university’s know-how.
“All of the compounds are on the market. A good chunk of them are already generic, and some are coming off-patent very soon,” Oxford Pharmascience chief executive Nigel Theobald revealed to Proactive Investors last week.
In keeping with Oxford Pharmascience's normal strategy, the company will be looking to see if it can reformulate the compounds, making them more effective and therefore suitable for commercial release.
robertalexander
- 02 Aug 2013 16:30
- 78 of 182
and ISA-able from 05 Aug 2013
dreamcatcher
- 02 Aug 2013 16:40
- 79 of 182
Did you see post 73 rob, hope it helped.
robertalexander
- 02 Aug 2013 18:22
- 80 of 182
DC, it did thanks though i got the date off of another thread somewhere on MoneyAM. i can't remember which one though.
roll on the 5th August
Alex
roll on the 5th August
Alex
dreamcatcher
- 02 Aug 2013 20:45
- 81 of 182
Only four days robertalexander. :-))
dreamcatcher
- 05 Aug 2013 16:40
- 82 of 182
Speciality pharma group Oxford Pharmascience's (LON:OXP) establishment of a Scientific Advisory Board and the appointment of Professor Bill Dawson indicate the progression of the group’s existing development plan remains on track, said house broker N+1 Singer.
"Momentum of moving towards human proof of concept trials in both the NSAIDs and Statin programmes continues to build. We re-iterate our upbeat view and believe the group is capable of becoming a major player in the reformulation market. We retain our 9.2p intrinsic value per share." Shares were 3.7p today.
http://www.proactiveinvestors.co.uk/columns/broker-spotlight/13757/broker-round-up-part-2-genel-advanced-computer-leni-gas-oil-13757.html
"Momentum of moving towards human proof of concept trials in both the NSAIDs and Statin programmes continues to build. We re-iterate our upbeat view and believe the group is capable of becoming a major player in the reformulation market. We retain our 9.2p intrinsic value per share." Shares were 3.7p today.
http://www.proactiveinvestors.co.uk/columns/broker-spotlight/13757/broker-round-up-part-2-genel-advanced-computer-leni-gas-oil-13757.html
ontheturn - 06 Sep 2013 12:24 - 83 of 182
On the move up today as some large buyers appeared earlier on.
The bounce is from support
The bounce is from support
ontheturn - 11 Sep 2013 16:44 - 84 of 182
Slowly but surely is on the up again today
doodlebug4 - 11 Sep 2013 16:54 - 85 of 182
It's very much a share that requires a lot of patience, but the potential here is enormous if all goes to plan and the various tests and trials prove positive.
dreamcatcher
- 18 Sep 2013 07:03
- 86 of 182
Half Yearly Report
RNS
RNS Number : 2445O
Oxford Pharmascience Group PLC
18 September 2013
Oxford Pharmascience Group plc
("Oxford Pharmascience" or "the Company")
Oxford Pharmascience publishes its interim results for the six months to 30 June 2013
Oxford Pharmascience Group Plc is pleased to announce its unaudited interim results for the six months to 30 June 2013.
Download
The full interim results are available to view and download via the following link:
http://www.rns-pdf.londonstockexchange.com/rns/2445O_-2013-9-17.pdf
Chairman's Statement
The first half of 2013 has seen continued progress in the growth of the business and evolution of Oxford Pharmascience into a drug re-development company with an exciting pipeline of innovative medicines with huge commercial potential.
The Group's strategy is now firmly established on re-developing already approved oral prescription and OTC products to address unmet patient needs with significant commercial potential. Focusing on off-patent drugs that have been approved and been in extensive use for a long time reduces both development and commercial risk and results in a simplified drug development regulatory pathway. This in turn allows for less expensive development programmes and faster access to market.
Having spent its initial years establishing its core technology platforms the group has refocused its activities on applying these technologies to developing improved formulations of existing drugs in the large pharmaceutical sectors of pain relief and cardiovascular treatments, specifically on NSAIDs and Statins. These are two of the largest drug categories in the world with combined sales of c $24bn and are dominated by off patent drugs. Re-developing these drugs to reduce side effects and improve compliance for the majority of patients taking these medicines is a compelling strategy and the group is well placed to deliver exciting new products in this manner.
The raising of a further £5m in March of this year has allowed the Group to push on with the development of taste masked ibuprofen products and its programme for new versions of the blockbuster drugs atorvastatin and simvastatin. In May we announced positive animal studies that showed the OXPzero™ technology could have the potential to reduce the risk for patients taking NSAIDs on a long term basis of developing ulcers and other serious gastric conditions. The Company has already begun to put in place a programme to develop ibuprofen tablets to reduce this gastric risk using the OXPzero™ ibuprofen salt it has already developed.
In addition we have recently strengthened our internal team and now have a strong scientific advisory board that has started providing guidance on the clinical programmes to bring these products to market.
Preparations to initiate this work are on-going and clinical programmes for ibuprofen and statins will begin in 2014. Full details will be published shortly along with key milestones to allow shareholders to monitor the progress of the programmes.
The future is incredibly exciting and existing business growth shows a glimpse of what the Group can do once its products reach market. Our calcium product continues to grow from strength to strength. Group sales for the first half of 2013 were £501,000, 47% higher than the same period last year and 7.5% higher than the whole of 2012. Strong growth in sales is expected to continue in the second half of 2013.
This is just the start of what the future has to offer for Oxford Pharmascience and I am delighted at the speed of transition the group has shown in the first 6 months of 2013
David Norwood
Chairman
18 September 2013
dreamcatcher
- 18 Sep 2013 15:54
- 87 of 182
Oxford Pharmascience shares up as revenues jump by half
By Jamie Nimmo September 18 2013, 3:27pm Oxford Pharma is now focused on being on a drug re-development companyOxford Pharma is now focused on being on a drug re-development company
--UPDATES SHARE PRICE--
Shares in AIM-listed Oxford Pharmascience (LON:OXP) received a shot in the arm on Wednesday when it revealed first-half revenues jumped 47% as it refocused the business on drug re-development.
The £501,000 generated in the six months to June 30 outstripped the total revenues from 2012, while the loss before tax increased slightly to £585,000, from £399,000 the year before.
It came as the company opted to redevelop existing oral drugs to make them better and easier to take instead of the previous emphasis on its technology platforms.
Shares rose 4.2% to 3.83p each on the news.
“The future is incredibly exciting and existing business growth shows a glimpse of what the group can do once its products reach market,” chairman David Norwood said in a statement.
“This is just the start of what the future has to offer for Oxford Pharmascience and I am delighted at the speed of transition the group has shown in the first 6 months of 2013.”
The shift in focus will see the company work predominantly on non-steroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen, and statins, used to reduce cholesterol, which have combined global sales of $24bn and are dominated by off-patent drugs.
NSAIDs and statins have serious side effects, which limit their use. Oxford Pharma plans to reformulate these drugs with reduced side effects.
The technologies it has been developing up to this point will be used to develop improved formulations of existing pain relief drugs and cardiovascular treatments.
Chief executive Nigel Theobald told Proactive Investors that redeveloping existing drugs is a quicker and cheaper way of getting a drug to market.
“Because they’re already proven to be safe and effective, bringing new versions of these drugs to market will take on average just two to three years at around £5mln a drug,” he explained.
“If we were developing a totally new drug in these areas, that would take over 10 years and cost over £1bn.
“For a fraction of the investment, you can see huge returns by redeveloping these existing drugs.”
Theobald added: “We’ve already established our technology platforms and seen the potential. So we’re now redeveloping existing drugs ourselves to make them better and easier to take.”
He said the second half of the year has started well, with Brazilian partner Aché launching a second version of the company’s calcium chew.
Theobald also highlighted the “massive deals” being done in the sector, pointing in particular to Sanofi’s recent deal with Oxford Pharma’s US peer Pozen.
The French pharma giant agreed to pay Pozen US$35mln earlier this month for a combination aspirin and omeprazole pill that avoids common side effects.
Oxford Pharma ended the six months with £6.65mln in cash, compared with just £639,000 in the same period last year.
N+1 Singer hailed a “solid” set of results from the company, highlighting the “impressive growth” shown in the numbers.
“The group’s ambition in both areas has potentially massive implications going forward and we continue to be extremely upbeat about the group as it continues its drive to become a major player in the re-formulation market,” said analyst Sheena Berry.
By Jamie Nimmo September 18 2013, 3:27pm Oxford Pharma is now focused on being on a drug re-development companyOxford Pharma is now focused on being on a drug re-development company
--UPDATES SHARE PRICE--
Shares in AIM-listed Oxford Pharmascience (LON:OXP) received a shot in the arm on Wednesday when it revealed first-half revenues jumped 47% as it refocused the business on drug re-development.
The £501,000 generated in the six months to June 30 outstripped the total revenues from 2012, while the loss before tax increased slightly to £585,000, from £399,000 the year before.
It came as the company opted to redevelop existing oral drugs to make them better and easier to take instead of the previous emphasis on its technology platforms.
Shares rose 4.2% to 3.83p each on the news.
“The future is incredibly exciting and existing business growth shows a glimpse of what the group can do once its products reach market,” chairman David Norwood said in a statement.
“This is just the start of what the future has to offer for Oxford Pharmascience and I am delighted at the speed of transition the group has shown in the first 6 months of 2013.”
The shift in focus will see the company work predominantly on non-steroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen, and statins, used to reduce cholesterol, which have combined global sales of $24bn and are dominated by off-patent drugs.
NSAIDs and statins have serious side effects, which limit their use. Oxford Pharma plans to reformulate these drugs with reduced side effects.
The technologies it has been developing up to this point will be used to develop improved formulations of existing pain relief drugs and cardiovascular treatments.
Chief executive Nigel Theobald told Proactive Investors that redeveloping existing drugs is a quicker and cheaper way of getting a drug to market.
“Because they’re already proven to be safe and effective, bringing new versions of these drugs to market will take on average just two to three years at around £5mln a drug,” he explained.
“If we were developing a totally new drug in these areas, that would take over 10 years and cost over £1bn.
“For a fraction of the investment, you can see huge returns by redeveloping these existing drugs.”
Theobald added: “We’ve already established our technology platforms and seen the potential. So we’re now redeveloping existing drugs ourselves to make them better and easier to take.”
He said the second half of the year has started well, with Brazilian partner Aché launching a second version of the company’s calcium chew.
Theobald also highlighted the “massive deals” being done in the sector, pointing in particular to Sanofi’s recent deal with Oxford Pharma’s US peer Pozen.
The French pharma giant agreed to pay Pozen US$35mln earlier this month for a combination aspirin and omeprazole pill that avoids common side effects.
Oxford Pharma ended the six months with £6.65mln in cash, compared with just £639,000 in the same period last year.
N+1 Singer hailed a “solid” set of results from the company, highlighting the “impressive growth” shown in the numbers.
“The group’s ambition in both areas has potentially massive implications going forward and we continue to be extremely upbeat about the group as it continues its drive to become a major player in the re-formulation market,” said analyst Sheena Berry.
dreamcatcher
- 18 Sep 2013 19:24
- 88 of 182
Oxford Pharmascience has 'exciting' potential as growth continues
By Jeremy Naylor September 18 2013, 8:54am
Nigel Theobald, CEO of Oxford Pharmascience (LON:OXP), tells Proactiveinvestors that the second half has started strongly. Having established the technology platforms Nigel says that the company is now focused on areas that have 'huge' potential.
http://www.proactiveinvestors.co.uk/companies/stocktube/2188/oxford-pharmascience-has-exciting-potential-as-growth-continues--2188.html
By Jeremy Naylor September 18 2013, 8:54am
Nigel Theobald, CEO of Oxford Pharmascience (LON:OXP), tells Proactiveinvestors that the second half has started strongly. Having established the technology platforms Nigel says that the company is now focused on areas that have 'huge' potential.
http://www.proactiveinvestors.co.uk/companies/stocktube/2188/oxford-pharmascience-has-exciting-potential-as-growth-continues--2188.html
dreamcatcher
- 19 Sep 2013 16:15
- 89 of 182
Oxford Pharmascience H1s indicate an 'exciting' redevelopment future
SharecastSharecast – 18 minutes ago..
LONDON (ShareCast) - Interim results from Oxford Pharmascience show the first small signs of an exciting future after it morphed into a drug re-development company.
Group sales for the first half of 2013 were 47% higher than the same period last year at £501,000 and 7.5% higher than the whole of 2012.
Chairman David Norwood, a serial director of innovative small cap companies and also a chess grandmaster, said: "The future is incredibly exciting and existing business growth shows a glimpse of what the group can do once its products reach market."
The new strategy involves using its core technology platforms to re-develop oral prescription drugs and over the counter drugs (OTC) that are already on the market so that they address unmet patient needs with significant commercial potential or are just more accessible, such as its making a better-tasting calcium and vitamin D supplement.
"Focusing on offpatent drugs that have been approved and been in extensive use for a long time reduces both development and commercial risk and results in a simplified drug development regulatory pathway," explained Norwood.
"This in turn allows for less expensive development programmes and faster access to market."
Norwood noted that the chewy calcium supplement continued to grow from strength to strength and across the group strong growth in sales was expected to continue in the second half of the year.
The AIM-listed company, which changed its name from Oxford Nutrascience in 2011, saw losses grow from £0.4m to £0.6m as administration expenses grew.
A £5m fundraising in March allowed OXP to push on with the development of taste-masked ibuprofen products and new versions of the blockbuster drugs atorvastatin and simvastatin for lowering cholesterol.
Shares in OXP were flat on Thursday at 3.83p.
doodlebug4 - 25 Sep 2013 12:14 - 90 of 182
Ticking up again - some news on the horizon?
dreamcatcher
- 25 Sep 2013 15:19
- 91 of 182
Oxford Pharma could become major player in re-formulation market, says N+1 Singer
By Giles Gwinnett September 25 2013, 8:33am The firm has shifted focus to developing products for the NSAID (non-steriod anti-inflammatory drug) and statin markets and clinical trials in both programmes are expected to begin next year, highlighted N+1 analyst Sheena BerryThe firm has shifted focus to developing products for the NSAID (non-steriod anti-inflammatory drug) and statin markets and clinical trials in both programmes are expected to begin next year, highlighted N+1 analyst Sheena Berry
Broker N+1 Singer is "extremely upbeat" about the prospects for Oxford Pharmascience (LON:OXP) as it transforms into a drug re-development company.
Following a "solid" set of interims last week, the broker has lifted its intrinsic value for the firm by 26% to 11.6 pence a share, from 9.2 pence previously.
Shares are currently changing hands at 3.95p each.
The firm has shifted focus to developing products for the NSAID (non-steriod anti-inflammatory drug) and statin markets and clinical trials in both programmes are expected to begin next year, highlighted N+1 analyst Sheena Berry.
It will re-develop existing oral drugs to make them better and easier to take instead of the company's previous emphasis on its technology platforms.
Speaking to Proactive last week, chief executive Nigel Theobald pointed to the “massive deals” being done in the sector and singled out Sanofi’s recent deal with Oxford Pharma’s US peer, Pozen.
The French pharma giant agreed to pay Pozen US$35mln earlier this month for a combination aspirin and omeprazole pill that avoids common side effects.
Analyst Berry noted that the Pozen and Sanofi-Aventis deal creates "a precedent" in this space, adding that Oxford has the ability "to take products to marketing authorisation itself, with the flexibility to consider and potentially establish partnerships in the interim".
"It is likely that the group will licence products on a market by market basis with the possibility of it entering certain markets on its own resources," she said.
"The group’s ambition in both areas has potentially massive implications going forward and we continue to be extremely upbeat about the group as it continues its drive to become a major player in the re-formulation market," she said.
Oxford Pharma’s recent interim results revealed it is well funded with £6.65mln in cash at the period-end.
The stock, meanwhile, has been a top performer as it has undergone its transformation under CEO Theobald and the team as it has advanced 155% in the past year.
However Singer’s price target points to further significant upside. “In our view, the group has a substantial opportunity to become a major player in the re-formulation market,” concluded Berry.
“Our valuation is based on risk adjusted ten-year net present value analyses of the group’s expected income streams. We are buoyant about the prospects that the group is capable of delivering.”
By Giles Gwinnett September 25 2013, 8:33am The firm has shifted focus to developing products for the NSAID (non-steriod anti-inflammatory drug) and statin markets and clinical trials in both programmes are expected to begin next year, highlighted N+1 analyst Sheena BerryThe firm has shifted focus to developing products for the NSAID (non-steriod anti-inflammatory drug) and statin markets and clinical trials in both programmes are expected to begin next year, highlighted N+1 analyst Sheena Berry
Broker N+1 Singer is "extremely upbeat" about the prospects for Oxford Pharmascience (LON:OXP) as it transforms into a drug re-development company.
Following a "solid" set of interims last week, the broker has lifted its intrinsic value for the firm by 26% to 11.6 pence a share, from 9.2 pence previously.
Shares are currently changing hands at 3.95p each.
The firm has shifted focus to developing products for the NSAID (non-steriod anti-inflammatory drug) and statin markets and clinical trials in both programmes are expected to begin next year, highlighted N+1 analyst Sheena Berry.
It will re-develop existing oral drugs to make them better and easier to take instead of the company's previous emphasis on its technology platforms.
Speaking to Proactive last week, chief executive Nigel Theobald pointed to the “massive deals” being done in the sector and singled out Sanofi’s recent deal with Oxford Pharma’s US peer, Pozen.
The French pharma giant agreed to pay Pozen US$35mln earlier this month for a combination aspirin and omeprazole pill that avoids common side effects.
Analyst Berry noted that the Pozen and Sanofi-Aventis deal creates "a precedent" in this space, adding that Oxford has the ability "to take products to marketing authorisation itself, with the flexibility to consider and potentially establish partnerships in the interim".
"It is likely that the group will licence products on a market by market basis with the possibility of it entering certain markets on its own resources," she said.
"The group’s ambition in both areas has potentially massive implications going forward and we continue to be extremely upbeat about the group as it continues its drive to become a major player in the re-formulation market," she said.
Oxford Pharma’s recent interim results revealed it is well funded with £6.65mln in cash at the period-end.
The stock, meanwhile, has been a top performer as it has undergone its transformation under CEO Theobald and the team as it has advanced 155% in the past year.
However Singer’s price target points to further significant upside. “In our view, the group has a substantial opportunity to become a major player in the re-formulation market,” concluded Berry.
“Our valuation is based on risk adjusted ten-year net present value analyses of the group’s expected income streams. We are buoyant about the prospects that the group is capable of delivering.”
| About MoneyAM | Ts and Cs | Privacy Policy | Investment Warning | Content Standards | Corporate Solutions | Advertise With Us | Site Map | © 2025 MoneyAM |
Register now for FREE
Share Prices,
Stock Quotes,
Charts, Bulletin Boards, Indices, Watchlists, Portfolio, Market News, Research
or see our Premium Services including Level 2, Terminal and much more.
Follow us on Twitter